Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure

Clinical Biochemistry

Volumn 47, Issue 12, 2014, Pages 1006-1009

  Gruson, D ^a   Mancini, M ^a   Ahn, S A ^a   Rousseau, M F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Architect; Biomarkers; BNP; Cost effectiveness; Galectin 3; Heart failure; Prognosis

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALECTIN 3;

ADULT; ARCHITECT ASSAY; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; GALECTIN 3 BLOOD LEVEL; HEALTH CARE COST; HEART FAILURE; HEART GRAFT; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; BLOOD; COST BENEFIT ANALYSIS; MIDDLE AGED; VALIDATION STUDY;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED;

EID: 84905731130     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.06.001     Document Type: Article

References (24)

1. Anand I.S., Rector T.S., Kuskowski M., et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013, 15:511-518.
2. Braunwald E., Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 2000, 102:IV14-IV23.
3. Carrasco Sanchez F.J. Galectin-3-independent prognosis in heart failure. Clin Res Cardiol 2011, 100:183.
4. Christenson R.H., Duh S.H., Wu A.H., et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010, 43:683-690.
5. Cooper D.N., Barondes S.H. God must love galectins; he made so many of them. Glycobiology 1999, 9:979-984.
6. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
7. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009, 11:811-817.
8. Devroey D., Van C.V. The incidence and first-year mortality of heart failure in Belgium: a 2-year nationwide prospective registration. Int J Clin Pract 2010, 64:330-335.
9. Gaze D.C., Prante C., Dreier J., et al. Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments. Clin Chem Lab Med 2014, 1-8.
10. Gruson D., Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?. Clin Biochem 2012, 45:719-726.
11. Gruson D., Lepoutre T., Ahn S.A., Ketelslegers J.M., Rousseau M.F. Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure. Clin Biochem 2013, 46:391-394.
12. Gruson D., Mancini M., Ahn S.A., Rousseau M.F. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction. Clin Chim Acta 2014, 429:189-193. [Epub;%2013 Dec 21.: 189-93]. 10.1016/j.cca.2013.12.017.
13. La'ulu S.L., Apple F.S., Murakami M.M., et al. Performance characteristics of the ARCHITECT galectin-3 assay. Clin Biochem 2013, 46:119-122.
14. Lee W.C., Chavez Y.E., Baker T., Luce B.R. Economic burden of heart failure: a summary of recent literature. Heart Lung 2004, 33:362-371.
15. Lin Y.H., Lin L.Y., Wu Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.
16. Lok D.J., Van Der Meer P., de la Porte P.W., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
17. Motiwala S.R., Szymonifka J., Belcher A., et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013, 15:1157-1163.
18. Mueller C. Cost-effectiveness of B-type natriuretic peptide testing. Congest Heart Fail 2008, 14:35-37.
19. Seetharaman J., Kanigsberg A., Slaaby R., et al. X-ray crystal structure of the human galectin-3 carbohydrate recognition domain at 2.1-A resolution. J Biol Chem 1998, 273:13047-13052.
20. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
21. Thygesen K., Mair J., Mueller C., et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012, 33:2001-2006.
22. van der Velde A.R., Gullestad L., Ueland T., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013, 6:219-226.
23. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 19(48):1217-1224.
24. Yancy C.W., Jessup M., Bozkurt B., et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 2013:10.